These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38530568)

  • 21. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
    Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E
    BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN).
    Chakravarthy U; Harding SP; Rogers CA; Downes S; Lotery AJ; Dakin HA; Culliford L; Scott LJ; Nash RL; Taylor J; Muldrew A; Sahni J; Wordsworth S; Raftery J; Peto T; Reeves BC
    Health Technol Assess; 2015 Oct; 19(78):1-298. PubMed ID: 26445075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment.
    Hatamnejad A; Dadak R; Orr S; Wykoff C; Choudhry N
    BMJ Open Ophthalmol; 2023 Jun; 8(1):. PubMed ID: 37493655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial.
    Kertes PJ; Galic IJ; Greve M; Williams G; Baker J; Lahaie M; Sheidow T
    JAMA Ophthalmol; 2020 Mar; 138(3):244-250. PubMed ID: 31917441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Boyer DS; Antoszyk AN; Steinle NC; Varenhorst MP; Pearlman JA; Gillies MC; Finger RP; Baldwin ME; Leitch IM
    Ophthalmol Retina; 2020 Mar; 4(3):250-263. PubMed ID: 31924544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study.
    Kunimoto D; Yoon YH; Wykoff CC; Chang A; Khurana RN; Maturi RK; Agostini H; Souied E; Chow DR; Lotery AJ; Ohji M; Bandello F; Belfort R; Li XY; Jiao J; Le G; Schmidt W; Hashad Y;
    Ophthalmology; 2020 Oct; 127(10):1331-1344. PubMed ID: 32471729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular Age-Related Macular Degeneration: A HARBOR Post Hoc Analysis.
    Lally DR; Hill L; Amador-Patarroyo MJ
    Ophthalmol Retina; 2022 Nov; 6(11):1054-1060. PubMed ID: 35654363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.
    Campochiaro PA; Marcus DM; Awh CC; Regillo C; Adamis AP; Bantseev V; Chiang Y; Ehrlich JS; Erickson S; Hanley WD; Horvath J; Maass KF; Singh N; Tang F; Barteselli G
    Ophthalmology; 2019 Aug; 126(8):1141-1154. PubMed ID: 30946888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
    Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial.
    Neffendorf JE; Desai R; Wang Y; Kelly J; Murphy C; Reeves BC; Chakravarthy U; Wordsworth S; Lewis C; Peacock J; Uddin S; O'Sullivan JM; Jackson TL
    Trials; 2016 Nov; 17(1):560. PubMed ID: 27881184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
    Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
    Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).
    Nguyen QD; Schachar RA; Nduaka CI; Sperling M; Klamerus KJ; Chi-Burris K; Yan E; Paggiarino DA; Rosenblatt I; Aitchison R; Erlich SS;
    Ophthalmology; 2012 Sep; 119(9):1867-73. PubMed ID: 22683252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.
    Berg K; Hadzalic E; Gjertsen I; Forsaa V; Berger LH; Kinge B; Henschien H; Fossen K; Markovic S; Pedersen TR; Sandvik L; Bragadóttir R
    Ophthalmology; 2016 Jan; 123(1):51-9. PubMed ID: 26477842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results.
    Regillo C; Berger B; Brooks L; Clark WL; Mittra R; Wykoff CC; Callaway NF; DeGraaf S; Ding HT; Fung AE; Gune S; Le Pogam S; Smith R; Willis JR; Barteselli G
    Ophthalmology; 2023 Jul; 130(7):735-747. PubMed ID: 36870451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
    Khanani AM; Patel SS; Ferrone PJ; Osborne A; Sahni J; Grzeschik S; Basu K; Ehrlich JS; Haskova Z; Dugel PU
    JAMA Ophthalmol; 2020 Sep; 138(9):964-972. PubMed ID: 32729897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR.
    Freund KB; Staurenghi G; Jung JJ; Zweifel SA; Cozzi M; Hill L; Blotner S; Tsuboi M; Gune S
    Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2437-2447. PubMed ID: 35239009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence.
    Chakraborty D; Mondal S; Boral S; Das A; Sinha TK; Majumdar S; Bhattacharya R; Maitra R
    Clin Ophthalmol; 2023; 17():1067-1076. PubMed ID: 37064960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration - results from the randomized, phase IIIb OCTAVE study.
    Staurenghi G; Garweg JG; Gerendas BS; Macfadden W; Gekkiev B; Margaron P; Dunger-Baldauf C; Kolar P
    BMC Ophthalmol; 2020 Jan; 20(1):18. PubMed ID: 31918685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.